Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity.

Somatostatin and dopamine are two major neurotransmitter systems that share a number of structural and functional characteristics. Somatostatin receptors and dopamine receptors are colocalized in neuronal subgroups, and somatostatin is involved in modulating dopamine-mediated control of motor activity. However, the molecular basis for such interaction between the two systems is unclear. Here, we show that dopamine receptor D2R and somatostatin receptor SSTR5 interact physically through hetero-oligomerization to create a novel receptor with enhanced functional activity. Our results provide evidence that receptors from different G protein (heterotrimeric guanine nucleotide binding protein)-coupled receptor families interact through oligomerization. Such direct intramembrane association defines a new level of molecular crosstalk between related G protein-coupled receptor subfamilies.

[1]  S. R. Nash,et al.  Dopamine receptors: from structure to function. , 1998, Physiological reviews.

[2]  T M Jovin,et al.  Oligomerization of epidermal growth factor receptors on A431 cells studied by time-resolved fluorescence imaging microscopy. A stereochemical model for tyrosine kinase receptor activation , 1995, The Journal of cell biology.

[3]  C. B. Srikant,et al.  Somatostatin receptors: identification and characterization in rat brain membranes. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[4]  Lakshmi A. Devi,et al.  G-protein-coupled receptor heterodimerization modulates receptor function , 1999, Nature.

[5]  U. Kumar,et al.  Subtypes of the Somatostatin Receptor Assemble as Functional Homo- and Heterodimers* , 2000, The Journal of Biological Chemistry.

[6]  S. Gauthier,et al.  Neurobehavioral effects of intrathecal somatostatinergic treatment in subhuman primates , 1988, Neurology.

[7]  A. Kastin,et al.  CNS effects of somatostatin. , 1978, Metabolism: clinical and experimental.

[8]  J. Epelbaum.  Somatostatin in the central nervous system: Physiology and pathological modifications , 1986, Progress in Neurobiology.

[9]  H. Friesen,et al.  Somatostatin and thyrotropin releasing hormone: Central effect on sleep and motor system , 1976, Pharmacology Biochemistry and Behavior.

[10]  J. Glowinski,et al.  Modulation by Monoamines of Somatostatin‐Sensitive Adenylate Cyclase on Neuronal and Glial Cells from the Mouse Brain in Primary Cultures , 1985, Journal of neurochemistry.

[11]  P. Seeman,et al.  Dopamine D2 receptor dimers and receptor-blocking peptides. , 1996, Biochemical and biophysical research communications.

[12]  F. Marshall,et al.  GABAB receptors - the first 7TM heterodimers. , 1999, Trends in pharmacological sciences.

[13]  M. Cohn,et al.  ‘Barrel rotation’ induced by somatostatin in the non-lesioned rat , 1975, Brain Research.

[14]  U. Kumar,et al.  The Cytoplasmic Tail of the Human Somatostatin Receptor Type 5 Is Crucial for Interaction with Adenylyl Cyclase and in Mediating Desensitization and Internalization* , 1998, The Journal of Biological Chemistry.

[15]  Michel Bouvier,et al.  Structural and functional aspects of G protein-coupled receptor oligomerization. , 1998 .

[16]  P. Seeman,et al.  A Transmembrane Domain-derived Peptide Inhibits D1 Dopamine Receptor Function without Affecting Receptor Oligomerization* , 1998, The Journal of Biological Chemistry.

[17]  Y. Patel.  Somatostatin and Its Receptor Family , 1999, Frontiers in Neuroendocrinology.

[18]  M. Thangaraju,et al.  Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. , 1999, Diabetes.

[19]  A. Saiardi,et al.  Dopamine D2 receptors in signal transduction and behavior. , 1997, Critical reviews in neurobiology.

[20]  C. Larsson,et al.  Acute effects of D1- and D2-receptor agonist and antagonist drugs on somatostatin binding, inhibition of adenylyl cyclase activity and accumulation of inositol 1,4,5-trisphosphate in the rat striatum. , 1997, Brain research. Molecular brain research.

[21]  J. Wess,et al.  Identification and Molecular Characterization of m3 Muscarinic Receptor Dimers* , 1999, The Journal of Biological Chemistry.

[22]  A. Levey,et al.  D1 and D2 dopamine receptor mRNA in rat brain. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L. Devi,et al.  Dimerization of the delta opioid receptor: implication for a role in receptor internalization. , 1997, The Journal of biological chemistry.